Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: A randomized, double-blind study

Journal of the American College of Cardiology

Volumn 31, Issue 6, 1998, Pages 1330-1335

  Mullen, Michael J ^a   Clarkson, Peter ^a   Donald, Ann E ^a   Thomson, Hyeyoung ^a   Thorne, Sara A ^a   Powe, Amanda J ^a   Furuno, Takashi ^a   Bull, Teresa ^a   Deanfield, John E ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; ECHOGRAPHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; ENALAPRIL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; REGRESSION ANALYSIS; VASODILATION;

EID: 0032080743     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00099-0     Document Type: Article

References (48)

1. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-5.
2. Pyörala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
3. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with the progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993;22:1141-54.
4. Lawrie GM, Morris GCJ, Glaeser DH. Influence of diabetes mellitus on the results of coronary bypass surgery: follow up of 212 diabetic patients 10 to 15 years after surgery. JAMA 1986;256:2967-71.
5. Myrup B, Mathiesen ER, Ronn B, Deckert T. Endothelial function and serum lipids in the course of developing microalbuminuria in insulin-dependent diabetes mellitus. Diabetes Research 1994;26:33-9.
6. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, Den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. The Lancet 1992;340:319-23.
7. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
8. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996;28:573-9.
9. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-6.
10. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-54.
11. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288: 373-6.
12. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide path-way present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-7.
13. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-6.
14. Sarkar R, Meinberg E, Stanley J, Gordon D, Webb R. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Cir Res 1996;78:225-30.
15. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vase Biol 1995;15:1652-9.
16. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors: a new trend? Circulation 1996;94:240-3.
17. Foris G, Dezso B, Fust M, Fust G. Effect of angiotensin II on macrophage functions. Immunology 1983;48:529-35.
18. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-6.
19. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
20. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-7.
21. Wiemer G, Scholkens BA, Becker RHA, and Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-63.
22. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
23. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18:S110-5.
24. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996;94:258-65.
25. Ruilope LM. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. J Hypertens Suppl 1995;13:S91-3.
26. Parving HH, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years experience. Am J Kidney Dis 1995;26:99-107.
27. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
28. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholesterol in plasma without use of a preparative centrifuge. Clin Chem 1972;18:499-502.
29. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
30. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41.
31. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90: 2056-69.
32. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
33. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
34. Clozel M, Kuhn H, Hefti F. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension 1991;18:132-41.
35. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kB activation monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
36. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18: 100-5.
37. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
38. Lees KR, MacFayden RJ, Reid JL. Tissue angiotensin converting enzyme inhibition: relevant to clinical practice? Am J Hypertens 1990;3:266S-72S.
39. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989;7: 11S-6S.
40. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolaemic young adults. J Clin Invest 1996;97:1989-94.
41. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-28.
42. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci 1995;88:245-55.
43. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432-8.
44. Wautier J, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996;97:238-43.
45. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-8.
46. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993;21:205-11.
47. Wu G, Meininger CJ. Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am J Physiol 1995;269:H1312-8.
48. DCCT (Diabetes Control and Complications Trial) Research Group. The effect of intensive treatment on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.